Galapagos Archives

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 4 Nov 2015

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

And here is the fourth interview I did at BIO-Europe 2015. This time, I am with Andre Hoekema, top-executive from the belgian Biotech success-story, Galapagos. We recently covered extensively the 400-employee company based north of Bruxelles. It made the biggest IPO ever by a EU Biotech on the NASDAQ, raising 270 million euros. It also recently had […]

November 4, 2015 - 1 minutemin - By Philip Hemme

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Oct 2015

What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes

Monday: AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping) Tuesday: Will Roche lose it’s Worldwide Leading position in Cancer treatments? Wednesday: CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9? Thursday: Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government Friday: Merck relinquishes Rare Disease license to instead […]

October 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 28 Sep 2015

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

What was AbbVie thinking? Backing out of a $1.4Bn deal to support Belgian biotech Galapagos’ rheumatoid arthritis candidate through its phase III, means NASDAQ stock is plummeting in value since Friday. With plans to work on its own phase II candidate instead, AbbVie is losing out on the potential of filgotinib, which will surely have […]

September 28, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Aug 2015

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for AbbVie, which is facing patent lost of its most profitable drug Humira. Mechelen, Belgium-based Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

GSK abandon its joint drug project with Galapagos

According to Reuters, Galapagos, a Belgian biotech group announced that GlaxoSmithKline has stopped a joint drug development project over concerns about adverse effects. In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical Proof of Concept. […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us